<p>India is expected to receive the first consignment of single-shot Johnson & Johnson Covid-19 vaccines in November or December, 2021, according to <a href="http://www.news18.com/news/india/covid-vaccine-tracker-jj-doses-expected-to-arrive-india-in-nov-dec-zydus-cadila-next-4082642.html" target="_blank">report </a>by <em>News 18 </em>quoting a government official.</p>.<p>Last week, the Central government gave <a href="https://www.deccanherald.com/national/north-and-central/johnson-and-johnsons-single-dose-covid-19-vaccine-approved-for-emergency-use-in-india-1017189.html" target="_blank">Emergency Use Authorization (EUA) to the J&J </a>vaccine.</p>.<p>With the approval J&J’s vaccines, India now has five vaccines for its nationwide immunisation drive. “This will further boost our nation's collective fight against Covid-19,” Health Minister Mansukh Mandaviya had said while announcing the grant of EUA to J&J.</p>.<p>India’s vaccine basket now has five vaccines – Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson & Johnson (J&J).</p>.<p>The official further told the publication that DCGI would soon give its nod to Zydus Cadila DNA-based Covid-19 dose. “We expect two crore doses monthly from Zydus Cadila," the source said.</p>.<p>India's vaccine supply pipeline is exepected to smoothen further as indigenously-developed Corbevax, manufactured by Hyderabad-based Biological-E and Covovax produced by Serum Institute too would be available for the vaccination drive soon.</p>.<p>Over the past week, Health Minister Mandaviya held meetings with vaccine manufacturers and took updates about the production capabilities of the vaccines.</p>.<p>Among those who met Mandaviya were Mahima Datla, Managing Director of Biological E, Serum Institute CEO Adar Poonawalla, Satish Reddy, Chairman of Dr Reddy’s Labs.</p>
<p>India is expected to receive the first consignment of single-shot Johnson & Johnson Covid-19 vaccines in November or December, 2021, according to <a href="http://www.news18.com/news/india/covid-vaccine-tracker-jj-doses-expected-to-arrive-india-in-nov-dec-zydus-cadila-next-4082642.html" target="_blank">report </a>by <em>News 18 </em>quoting a government official.</p>.<p>Last week, the Central government gave <a href="https://www.deccanherald.com/national/north-and-central/johnson-and-johnsons-single-dose-covid-19-vaccine-approved-for-emergency-use-in-india-1017189.html" target="_blank">Emergency Use Authorization (EUA) to the J&J </a>vaccine.</p>.<p>With the approval J&J’s vaccines, India now has five vaccines for its nationwide immunisation drive. “This will further boost our nation's collective fight against Covid-19,” Health Minister Mansukh Mandaviya had said while announcing the grant of EUA to J&J.</p>.<p>India’s vaccine basket now has five vaccines – Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson & Johnson (J&J).</p>.<p>The official further told the publication that DCGI would soon give its nod to Zydus Cadila DNA-based Covid-19 dose. “We expect two crore doses monthly from Zydus Cadila," the source said.</p>.<p>India's vaccine supply pipeline is exepected to smoothen further as indigenously-developed Corbevax, manufactured by Hyderabad-based Biological-E and Covovax produced by Serum Institute too would be available for the vaccination drive soon.</p>.<p>Over the past week, Health Minister Mandaviya held meetings with vaccine manufacturers and took updates about the production capabilities of the vaccines.</p>.<p>Among those who met Mandaviya were Mahima Datla, Managing Director of Biological E, Serum Institute CEO Adar Poonawalla, Satish Reddy, Chairman of Dr Reddy’s Labs.</p>
